Biopharmaceutical companies aren’t really known for positive progression in their stocks and even in growth and expansion trends, but 2014 has been quite a generous year for such companies. The S&P 500 index fared quite well this year and the reason behind that were healthcare companies doing well. One such company is Amgen Inc. (NASDAQ:AMGN), which posted 50 percent gain in 2014. Amgen Inc. (NASDAQ:AMGN)’s revenue came from successful late stage trials for numerous drugs. This has led to the company rolling out consistent growth in its core area and growth in the top-line area. Such growth would have been unimaginable for biopharmaceutical companies in the past 5 years.
Amgen Inc. (NASDAQ:AMGN) has been holding an impressive pipeline with drugs that have the potential of creating an instant boom in the health market. The pipelines consists of 10 compounds which are either in the stage of getting approval from the Food and Drug administration or in the third test phase, due to be released in 2015-2016. There’s a lot Amgen Inc. (NASDAQ:AMGN) has to offer to the health market in the future.
The foremost drug in Amgen Inc. (NASDAQ:AMGN)’s pipeline is Evolocumab, which works upon removing low density lipoprotein from the bloodstream of the patients. This drug could prove to be ground breaking for the rising number of patients of high-triglycerides.
Amgen Inc. (NASDAQ:AMGN)’s cancer drug called Kyprolis has been making quite a roar as a third line treatment but Amgen Inc. (NASDAQ:AMGN) is pushing for the drug to make a transition into the second line. Kyprolis sales have been growing and even got upped by 21 percent in the third quarter, but it all comes down to the drug getting its label indication, or else the annual sales will be adversely affected.
Shareholders of the company will be commending themselves for investing in the stock if the compounds in Amgen Inc. (NASDAQ:AMGN)’s pipeline make heavy sales in the overseas market. Amgen Inc. (NASDAQ:AMGN) is looking to hit the global health sector because of scope of the drugs it has in the pipeline. Cancer drug and the high-triglyceride therapy will be needed all around the world because these are common diseases in almost every other country. The emphasis of Amgen Inc. (NASDAQ:AMGN) is on its cancer drug, because numerous developments have been made in this category, and Kyprolis has got a healthy curing rate.
Amgen (NASDAQ:AMGN) is looking to end its reliance on the US market, or at least minimize it because for a pharmaceutical company to rely upon one market could prove to be dangerous in the long run. Amgen Inc. (NASDAQ:AMGN) is looking to appeal to a wider audience, globally. Not only will it increase Amgen (NASDAQ:AMGN)’s sales making capability, it will also give Amgen Inc. (NASDAQ:AMGN) the global recognition it deserves. And if the company keeps going on the right track, it will be looking at glorious years ahead. Amgen Inc. (NASDAQ:AMGN) should benefit from the golden run it currently enjoys in the health market while the glory lasts.